Assays for Serodiagnosis of Prostate Cancer
In this study, five serologic assays for prostate cancer were compared. immunoenzymometric assay for Prostate-specific antigen (PSA-E), immunoradiometric assay for Prostate-specific antigen (PSA-R), immunoenzymometric assay for prostatic acid phosphatase (PAP-E), immunoradiometric assay for Prostatic acid phosphatase (PAP-R), and a traditional colorimetric assay for prostatic acid phosphatase (PAP-C). Precision, linearity, and analytical sensitivity for all the assays were good. There was excellent correlation between the two PSA assays (r=0.973), good correlation between the two immunologic tests for PAP (r=0.785), and poor correlation with the colorimetric test for PAP (r=0.041). Sera from 200 healthy male subjects were assayed, and reference intervals and decision values were established. Sera from 519 patients were assayed in a random-blind manner. The results were correlated with diagnoses which were established histologically. Samples included 189 patients with prostate cancer, 252 with benign prostatic hyperplasia, and 78 with miscellaneous genitourinary pathologies. Using the selected decision values, the diagnostic efficiencies for the assays were established as: PSA-E, 67.2%; PSA-R, 66.9%; PAP-E, 68.2%; PAP-R, 58.5%; and PAP-C, 42.9%. We eliminated from the study 94 patients who were receiving cancer therapy, so the recalculated diagnostic efficiencies were: PSA-E, 81.4%; PSA-R, 81.4%; PAP-E, 81.2%; PAP-R, 74.2%; and PAP-C, 57.9%.
Johnson, J. T.,
(1992). Assays for Serodiagnosis of Prostate Cancer. Laboratory Medicine, 23(9), 607-612.
Available at: http://aquila.usm.edu/fac_pubs/6861